Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 22,816

Document Document Title
WO/2019/002015A1
The invention relates to novel steroidal 17-beta heteroaryl compounds as AKR1C3 inhibitors, to the use thereof for the treatment and/or prophylaxis of diseases and to the use thereof for the production of medicaments for treatment and/or...  
WO/2019/004088A1
The present invention addresses the problem of providing a mucoadhesive oral preparation which shows a high drug absorption rate and a high drug release speed. As a means for solving this problem, provided is a mucoadhesive oral preparat...  
WO/2018/234255A1
The invention relates to the use of at least one strain of Lactobacillus plantarum in a method for increasing the numbers of Oscillospira spp. in a subject and preferably maintaining the increased numbers, the method comprising administe...  
WO/2018/230588A1
As a cell-sealing device with which it is possible to seal a larger cell mass due to sufficient oxygen being supplied to cells in an implant part, there is provided a cell-sealing device in which a plurality of capsule-form structures, i...  
WO/2018/224736A2
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...  
WO/2018/220623A1
Disclosed is a three-dimensional (3D) cell cluster comprising transdifferentiated adult mammalian non-pancreatic beta cells having a mature pancreatic beta cell phenotype and function, wherein the transdifferentiated cells have an enhanc...  
WO/2018/221679A1
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.  
WO/2018/209415A1
The present invention falls within the fields of pharmacy, medicine, chemistry and biotechnology. The compound of the present invention is a peptide and has shown surprising stability and ease of handling in comparison to the most simila...  
WO/2018/210207A1
A compound as represented by formula (I), and optical isomers, solvates, pharmaceutically-acceptable salts, or prodrugs thereof. The present invention has urate transporter 1 (URAT1) inhibitory activity, can be used for treatment of gout...  
WO/2018/213772A1
Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. The methods are designed to provide optimum plasma testosterone levels over an extended period.  
WO/2018/206959A1
The present invention relates to orexin receptor antagonists, pharmaceutical compositi comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists as m...  
WO/2018/206956A1
The present invention relates to orexin receptor antagonists, pharmaceutical compositions comprising the antagonists, methods of making the antagonists, their use for the modulation of the orexin receptor, and to use of the antagonists a...  
WO/2018/207171A1
The present invention discloses bimodal modified release fixed-dose combination (FDC) compositions and therapeutic methods for treatment of cancer by administration to a patient in need thereof of a FDC composition comprising a first act...  
WO/2018/203048A1
The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a ...  
WO/2018/199166A1
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...  
WO/2018/197698A1
The present invention provides novel softgel capsules of a women health care hormone, as well as to a process for the preparation thereof. In particular, the present invention relates to novel softgel capsules of a women health care horm...  
WO/2018/189212A1
The invention relates to non-deliquescent acid addition salts of elagolix with strong acids, for example selected from the group consisting of sulfuric acid and hydrochloric acid, to processes for their preparation and to a pharmaceutica...  
WO/2018/189213A1
The invention relates to an amorphous solid dispersion comprising elagolix sodium and at least one silicon-based inorganic compound and to a process for preparing the same. Furthermore, it relates to a pharmaceutical composition comprisi...  
WO/2018/191522A1
The present disclosure provides methods of treating polycystic ovary syndrome (PCOS) with tetrahydro-iso-alpha acid (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof, in part...  
WO/2018/185131A3
This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, ...  
WO/2018/184523A1
A composition comprising a grape seed extract and a black tea extract. The composition can increase testosterone secretion more effectively than a single component, and can be used for preparing pharmaceutical compositions, foods, health...  
WO/2018/185131A2
This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, ...  
WO/2018/184115A1
Compounds comprising quinazolinone derivatives and methods of identification and use of imaging agents. The compounds have the general formula I: wherein R2 is selected from halogen, halosubstituted alkyl, alkyl, hydroxyl-alkyl, and amin...  
WO/2018/186366A1
The present invention addresses the problem of providing a novel cyclin-dependent kinase 8 and/or 19 inhibitor that is useful as an anticancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor that c...  
WO/2018/186953A1
Described are macro-capsules and barriers that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.  
WO/2018/177993A1
The invention relates, inter alia, to compounds of general formula (I). The invention also relates to methods for synthesizing the compounds of formula (I). The compounds according to the invention are in particular suitable for controll...  
WO/2018/177381A1
The invention relates to the field of pharmaceutical chemistry, and particularly relates to a compound represented by formula (I), a preparation method thereof, and a medical use thereof. In the compound represented by formula (I), a lac...  
WO/2018/174283A1
Provided is a sustained-release formulation of evocalcet or a pharmacologically acceptable salt thereof. A polyethylene glycol derivative of evocalcet or a pharmacologically acceptable salt thereof is used.  
WO/2018/168879A1
[Problem] To provide a composition having an estrogen-like action which comprises a hot water extract of Sparassis crispa mycelia.  
WO/2018/166468A1
Disclosed are an IgG-like long-acting immune fusion protein and the use thereof. The IgG-like long-acting immune fusion protein consists of an effector molecule and a constant region of an IgG antibody, and the effector molecule is linke...  
WO/2018/166494A1
The present disclosure relates to the use of a compound as shown in formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diabetes mellitus, or the use of same in the...  
WO/2018/165933A1
Polypeptide for regulating saccharometabolism and uses thereof in the preparation of drugs for treating diseases related to saccharometabolism. The polypeptide can reduce blood sugar, can promote insulin secretion, can be used in the pre...  
WO/2018/159522A1
Provided is a food composition for preventing or alleviating metabolic syndrome, the food composition containing, as active ingredients, a 67 kDa laminine receptor (67LR) agonist and a sulfur-containing compound found from an allium plan...  
WO/2018/157202A1
The present invention is a delivery system for sublingual and/or buccal delivery comprising at least one functional oil (i.e. acting as an oil delivery base); at least one surfactant; and at least one pharmaceutically active agent. The i...  
WO/2018/155622A1
By suppressing the loss of living cells or living tissue during the production of a PVA gel that contains living cells or living tissue, the present invention addresses the problem of supplying a cell- or tissue-embedding device that has...  
WO/2018/153849A1
The present invention relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relate...  
WO/2018/148666A1
It is disclosed herein that a FAK inhibitor induces conversion of acinar cells into beta cells. Methods are provided for increasing beta cell proliferation by administering an effective amount of a FAK inhibitor to a subject in need ther...  
WO/2018/147300A1
Provided is a somatostatin receptor subtype 2 agonist. A compound disclosed in the present invention that is represented by general formula (I) (wherein each symbol has the same meaning as defined in the description) or a salt thereof is...  
WO/2018/146473A1
The present invention relates generally to polypeptides or nucleic acids for use in the treatment, management, retardation of progression or normalisation of development of an iduronate-2-sulfatase (IDS) deficiency and/or Mucopolysacchar...  
WO/2018/136890A1
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...  
WO/2018/130174A1
Disclosed are a pyrrolo[2,3-c]pyridine derivative, a preparation method therefor, and use thereof in medicine. Specifically, disclosed are a pyrrolo[2,3-c]pyridine derivative as represented by general formula (1), a preparation method th...  
WO/2018/129395A1
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.  
WO/2018/122409A1
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions...  
WO/2018/123910A1
[Problem] To provide a composition with which it is possible to promote increase in androgen. [Solution] Provided is a composition for promoting increase in androgen, and which contains compound K. This composition for promoting increase...  
WO/2018/124009A1
The purpose of the present invention is to provide a prophylactic or ameliorating agent for hypothermia which is effective against hypothermia. Specifically provided is a prophylactic or ameliorating agent for hypothermia which compris...  
WO/2018/118691A1
Disclosed herein are methods for determining inflammation in subjects. Also disclosed are methods for determining whether a subject has sepsis. The methods include determining methylation of preproinsulin DNA.  
WO/2018/114670A1
The present invention covers [4-(phenylsulfonyl)piperazin-1-yl](1H-1,2,3-triazol-4- yl)methanone compounds of general formula (I): (I), in which Q, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, interme...  
WO/2018/103726A1
Provided are a crystal form of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquin azolin-4(3H)-one represented by Formula I, a preparation method and a use thereof. The present invention belongs ...  
WO/2018/100776A1
Provided is a technique for decomposing a resveratrol glycoside, preferably decomposing a resveratrol glycoside and an isoflavone glycoside, and thus promoting aglycone production to thereby increase the absorbability thereof into a livi...  
WO/2018/099363A1
Provided is the use of an insulin-like growth factor-2 for preparing a pharmaceutical composition, wherein the pharmaceutical composition is used for (i) promoting the expression of the macrophage PD-L1, and/or (ii) inhibiting the expres...  

Matches 1 - 50 out of 22,816